Eris Lifesciences
Ticker > Company >

Eris Lifesciences share price

Eris Lifesciences Ltd.

NSE: ERIS BSE: 540596 SECTOR: Pharmaceuticals & Drugs  92k   297   43

1443.90
+41.85 (2.98%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 1473.7

Today's Low

₹ 1398

52 Week High

₹ 1593

52 Week Low

₹ 815.5

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 19663.76 Cr.

Enterprise Value

₹ 20896.47 Cr.

No. of Shares

13.62 Cr.

P/E

227.51

P/B

7.63

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  189.35

CASH

₹ 1296.74 Cr.

DEBT

₹ 2529.45 Cr.

Promoter Holding

54.85 %

EPS (TTM)

₹  6.35

Sales Growth

11.72%

ROE

12.65 %

ROCE

10.18%

Profit Growth

-24.7 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Eris Lifesciences Ltd.

GLIMISAVE ERITEL OLMIN TENDIA RENERVE REMYLIN RABONIK TAYO LNBLOC CYBLEX ATORSAVE ROSIFLEX CREVAST RARICAP SERLIFT

Index Presence

The company is present in 18 Indices.

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
42931.55
  1643 (3.97931145559725%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
40784.05
  562.900000000001 (1.39951244556658%)

NFT500MULTI

Nifty500 Multifactor MQVLv 50
30255.8
  944.099999999999 (3.22089813965072%)

NIFTY500

Nifty 500
22511.4
  835.850000000002 (3.85618819360987%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
18643
  689.25 (3.83903084313861%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
16885.7
  629.400000000001 (3.87172972939722%)

NIFTYSMALLCAP250

Nifty Smallcap 250
15684.2
  603.75 (4.00352774618795%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15458.25
  575.85 (3.86933559103371%)

NFT500EQUAL

Nifty 500 Equal Weight
13296.75
  510.200000000001 (3.99013025405603%)

NIFTYTOTALMCAP

Nifty Total Market index
12640.6
  472.550000000001 (3.88353105057919%)

SMLCAP

S&P Bse Small Cap
49176.68
  482.93 (0.991769991015268%)

BSE HC

S&P Bse Healthcare
41998.59
  399.299999999996 (0.95987215166411%)

BSE500

S&P Bse 500
35144.23
  -268.169999999998 (-0.757277111972077%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
11351.79
  33.5 (0.295981106686605%)

BSE1000

Bse 1000
10443.08
  -68.4799999999996 (-0.651473235181077%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SML250

S&P Bse 250 SmallCap
6343.52
  49.3200000000006 (0.783578532617346%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year11.72%
3 Year10.27%
5 Year10.64%

Profit Growth

1 Year-24.7%
3 Year-5.09%
5 Year0.98%

ROE%

1 Year12.65%
3 Year18.61%
5 Year20.81%

ROCE %

1 Year10.18%
3 Year19.04%
5 Year21.8%

Debt/Equity

1.0042

Price to Cash Flow

58.47

Interest Cover Ratio

6.7268

CFO/PAT (5 Yr. Avg.)

0.961234432553445

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 54.85 18.51
Dec 2024 54.86 18.51
Sep 2024 54.87 18.51
Jun 2024 54.88 18.51
Mar 2024 54.90 18.51
Investors List
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 35.2004273030311% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -71.5971 days.

 Limitations

  • The company has shown a poor profit growth of -5.09363449473875% for the Past 3 years.
  • The company has shown a poor revenue growth of 10.2687442436507% for the Past 3 years.
  • Tax rate is low at 8.8559.
  • The company is trading at a high EV/EBITDA of 45.6608.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 324.41 341.3 456.69 436.56 399.73
Total Expenditure 249.98 261.91 333.31 293.93 300.16
Operating Profit 74.43 79.39 123.38 142.63 99.57
Other Income 3.43 20.39 5.16 5.81 7.79
Interest 15.14 28.89 56.17 56.26 54.65
Depreciation 28.08 29.14 45.55 46.16 46.68
Exceptional Items 0 0 0 0 0
Profit Before Tax 34.64 41.75 26.82 46.02 6.03
Tax 2.99 2.24 9.78 17.92 4.25
Profit After Tax 31.65 39.51 17.04 28.1 1.78
Adjusted EPS (Rs) 2.33 2.9 1.25 2.06 0.13

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1020.23 1108.83 1215.73 1330.73 1486.71
Total Expenditure 665.28 691.36 731.68 825.61 1032.89
Operating Profit 354.96 417.47 484.06 505.11 453.81
Other Income 15.49 10 28.99 17.26 34.83
Interest 1.97 0.94 3.05 20.81 57.42
Depreciation 44.88 37.64 51.46 64.66 102.39
Exceptional Items 0 0 0 0 0
Profit Before Tax 323.59 388.89 458.54 436.91 328.83
Tax 32.32 38.29 41.35 38.9 29.12
Net Profit 291.27 350.61 417.19 398.01 299.71
Adjusted EPS (Rs.) 21.45 25.82 30.69 29.27 22.03

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 13.58 13.58 13.59 13.6 13.6
Total Reserves 1286.12 1561.89 1904.96 2208.29 2510.42
Borrowings 0 0 0 209.47 485.94
Other N/C liabilities -130.18 -161.82 -170.49 -205.26 -225.96
Current liabilities 203.06 212.42 249.79 361.73 2322.54
Total Liabilities 1372.59 1626.08 1997.86 2587.83 5106.54
Assets
Net Block 600.64 584.32 642 897.81 1515.56
Capital WIP 0 0 0 0 0
Intangible WIP 4.37 1.56 2.98 0.34 0.61
Investments 246.03 480.97 678.18 966.52 1618.95
Loans & Advances 15.44 25.36 11.14 85.95 27.05
Other N/C Assets 2.88 42.27 0 7.18 7.08
Current Assets 503.22 491.6 663.56 630.03 1937.31
Total Assets 1372.59 1626.08 1997.86 2587.83 5106.54
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 323.59 388.89 458.54 436.91 328.83
Adjustment 39.36 36.11 31.04 73.7 144.13
Changes in Assets & Liabilities -47.37 38.44 -37.26 -110.5 -63.19
Tax Paid -50.34 -68.04 -82.9 -77.79 -73.48
Operating Cash Flow 265.25 395.41 369.41 322.33 336.29
Investing Cash Flow 126.74 -347.86 -267.64 -513.3 -2491.89
Financing Cash Flow -333.52 -81.13 -88.42 193.75 2160.06
Net Cash Flow 58.47 -33.58 13.36 2.78 4.45

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 54.90 54.88 54.87 54.86 54.85
amit indubhusan bakshi - 42.87 42.86 42.85 42.84
inderjeet singh negi 4.37 4.37 4.36 4.36 4.36
kaushal kamleshkumar shah... 3.29 3.28 3.28 3.28 3.28
rajendrakumar rambhai pat... 4.37 4.37 4.36 4.36 4.36
amit indubhushan bakshi 42.88 - - - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 45.10 45.12 45.13 45.14 45.15
bhikhalal chimanlal shah 2.76 2.76 1.97 1.97 1.97
franklin india smaller co... 1.46 1.46 3.59 3.55 3.37
hdfc small cap fund 6.60 7.76 7.54 7.42 7.82
hetal rasiklal shah 2.58 2.40 2.20 2.20 2.20
lilac investments limited... - - 7.26 8.79 8.79
llp 0.04 - 0.04 0.03 0.05
rakesh shah 4.88 4.88 2.92 1.45 1.45
uti-flexi cap fund - - - - 3.00
uti flexi cap fund 4.14 3.95 3.81 3.41 -
emerald investments limit... 7.27 7.27 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Eris Lifesciences informs about investor call 13 May, 5:33 PM Eris Lifesciences submits analyst meet intimation 13 May, 5:04 PM Eris Lifesciences informs about board meeting 13 May, 4:47 PM Eris Lifesciences Informs about clarification on increase in volume 21 Mar, 4:51 PM Eris Lifesciences informs about allotment of ESOP 6 Mar, 2:24 PM Eris Lifesciences informs about analyst meet 24 Feb, 11:46 AM Eris Lifesciences informs about disclosure 21 Feb, 9:35 AM Eris Lifesciences - Quaterly Results 4 Feb, 12:45 PM Eris Lifesciences - Quaterly Results 4 Feb, 12:45 PM Eris Lifesciences - Quaterly Results 4 Feb, 12:45 PM Eris Lifesciences informs about board meeting 29 Jan, 2:52 PM Eris Lifesciences informs about investor meet 4 Dec, 5:17 PM Eris Lifesciences - Quaterly Results 25 Oct, 1:21 PM Eris Lifesciences - Quaterly Results 25 Oct, 1:21 PM Eris Lifesciences - Quaterly Results 25 Oct, 1:21 PM Eris Lifesciences acquires 100% stake in Chemman Labs 15 Oct, 12:15 PM Eris Lifesciences informs about analyst meet 13 Sep, 3:19 PM Eris Lifesciences informs about disclosure 26 Aug, 5:26 PM Eris Lifesciences informs about disclosure 26 Aug, 5:05 PM Eris Lifesciences to acquire 100% stake in Chemman Labs 2 Aug, 4:11 PM Eris Lifesciences - Quaterly Results 2 Aug, 2:31 PM Eris Lifesciences - Quaterly Results 2 Aug, 2:31 PM Eris Lifesciences - Quaterly Results 2 Aug, 2:31 PM Eris Lifesciences informs about allotment of equity shares under ESOP 24 Jun, 2:30 PM Eris Lifesciences completes acquisition of 19% equity stake in Swiss Parenterals 12 Jun, 10:14 AM Eris Lifesciences informs about analyst meet 31 May, 4:23 PM Eris Lifesciences gets nod to raise up to Rs 1250 crore via NCDs 21 May, 6:14 PM Eris Lifesciences - Quaterly Results 21 May, 4:53 PM Eris Lifesciences - Quaterly Results 21 May, 4:53 PM Eris Lifesciences - Quaterly Results 21 May, 4:53 PM Eris Lifesciences informs about update on board meeting 17 May, 3:45 PM Eris Lifesciences planning to raise funds 17 May, 12:44 PM Eris Lifesciences informs about analyst meet 21 Mar, 4:50 PM Eris Lifesciences acquires Biocon Biologics’ India branded formulation business 15 Mar, 10:59 AM Eris Lifesciences informs about outcome of board meeting 14 Mar, 4:56 PM Eris Lifesciences informs about transcript of investor call 20 Feb, 3:35 PM Eris Lifesciences acquires 51% stake in Swiss Parenterals 16 Feb, 11:53 AM Eris Lifesciences - Quaterly Results 13 Feb, 3:35 PM Eris Lifesciences - Quaterly Results 13 Feb, 3:35 PM Eris Lifesciences - Quaterly Results 13 Feb, 3:35 PM Eris Lifesciences informs about disclosure 9 Nov, 10:39 AM Eris Lifesciences - Quaterly Results 8 Nov, 2:22 PM Eris Lifesciences - Quaterly Results 8 Nov, 2:22 PM Eris Lifesciences - Quaterly Results 8 Nov, 2:22 PM Eris Lifesciences informs about confirmation certificate 12 Oct, 4:56 PM Eris Lifesciences informs about analyst meet 20 Sep, 2:19 PM Eris Lifesciences informs about analyst meet 6 Sep, 10:48 AM Eris Lifesciences to avail rupee term loan facility of Rs 120.82 crore from Citi Bank N.A. 22 Aug, 11:18 AM Eris Lifesciences - Quaterly Results 7 Aug, 1:00 PM Eris Lifesciences - Quaterly Results 7 Aug, 1:00 PM

Eris Lifesciences Stock Price Analysis and Quick Research Report. Is Eris Lifesciences an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Eris Lifesciences and its performance over the period of time. Eris Lifesciences stock price today is Rs 1404.9.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Eris Lifesciences cash from the operating activity was Rs 336.289 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Eris Lifesciences has a Debt to Equity ratio of 1.0042 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Eris Lifesciences , the EPS growth was -24.719 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Eris Lifesciences has OPM of 30.5247977744087 % which is a good sign for profitability.
     
  • ROE: Eris Lifesciences have a average ROE of 12.6513 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Eris Lifesciences is Rs 1404.9. One can use valuation calculators of ticker to know if Eris Lifesciences share price is undervalued or overvalued.
Last Updated on:
Brief about Eris Lifesciences

Eris Lifesciences Ltd. Financials: Check Share price, Balance Sheet, Annual report, and Quarterly Results for company analysis

Eris Lifesciences Ltd.'s stock analysis page provides long-term investors with the necessary tools and resources to make informed investment decisions. These tools and resources include share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders analysis. Our website also offers pre-built screening tools to analyze the stock's performance compared to its peers and premium feature tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. Annual reports and quarterly results are provided as downloadable documents for in-depth analysis.

Eris Lifesciences Ltd. Share Price Analysis:


When assessing long-term investment opportunities, analyzing Eris Lifesciences Ltd.'s share price is a critical factor. Our stock analysis page provides historical share price charts, which are a valuable resource for users to monitor the company's performance over time. Further analysis of this data can then be conducted using our pre-built screening tools to help investors analyze Eris Lifesciences Ltd.'s share price performance better. The analysis includes tracking the company's stock prices regularly, charting trends and assessing the future performance potential. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions. 

Eris Lifesciences Ltd. Balance Sheet Analysis:


Eris Lifesciences Ltd.'s balance sheet is a crucial indicator of the company's financial strength and stability. A thorough analysis of the balance sheet is essential for investors to understand the company's financial health and assess growth potential accurately. Our website offers access to Eris Lifesciences Ltd.'s balance sheet as a downloadable document, which users can use to perform an in-depth analysis for long-term investment decisions. Further analysis can be conducted using our premium feature tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis.

Eris Lifesciences Ltd. Annual Report Analysis:


Eris Lifesciences Ltd.'s annual report provides critical information for long-term investors regarding the company's strategic initiatives and financial performance. Understanding the annual report is essential for long-term investors since it offers insights into the company's future growth trajectory. Our website offers access to Eris Lifesciences Ltd.'s annual report as a downloadable document, which investors can use for an in-depth analysis of the company's performance. Our pre-built screening tools can assist investors in analyzing the company's performance compared to its peers, which can allow for better decision-making.

Eris Lifesciences Ltd. Dividend Analysis:


Dividend payout policies are an essential factor for long-term investors considering the viability of investing in any company's stock. Eris Lifesciences Ltd.'s dividend payout trends are a factor that investors should consider when assessing the stock's potential. Ticker features insights into Eris Lifesciences Ltd.'s dividend payout trends, which can assist long-term investors in analyzing the stock's viability as a long-term investment option.

Eris Lifesciences Ltd. Quarterly Results Analysis:


Eris Lifesciences Ltd.'s quarterly results hold critical information regarding the company's financial performance, including revenue, profits, and losses. The data from these reports can be used by long-term investors to assess the company's growth potential. Our website provides a downloadable copy of Eris Lifesciences Ltd.'s quarterly results, which investors can use to make informed analysis of the company's financial health for long-term investment decisions. Further analysis of this data can be conducted using our premium feature tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Eris Lifesciences Ltd. Stock Price Analysis:


Monitoring Eris Lifesciences Ltd.'s stock prices is critical to analyzing the stock's overall performance. Our stock analysis page features current stock price updates which investors can access to assess market trends and potential investment opportunities. Ticker's pre-built screening tools can help investors analyze the stock's performance compared to its peers and help investors make informed investment decisions for the long term. Our website provides pre-built screening tools to help investors analyze stock price and performance.

Eris Lifesciences Ltd. Price Chart Analysis:


A visual representation of Eris Lifesciences Ltd.'s share price trends over a period is an essential tool for long-term investors. It helps investors track the company's performance over time and make informed investment decisions. Ticker provides investors with a price chart to visualize Eris Lifesciences Ltd.'s share price trends over a specific period. Our pre-built screening tools can assist investors in analyzing the company's performance compared to its peers, which can allow for better decision-making.

Eris Lifesciences Ltd. News Analysis:


Keeping up with Eris Lifesciences Ltd.'s recent news and developments is crucial for investors. Our website provides timely news articles related to Eris Lifesciences Ltd. to provide investors with up-to-date insights into the stock's performance. The news section of our website offers reliable information on important events, regulatory changes, and other factors that may impact the stock's performance. Our pre-built screening tools can also provide investors with information about the company's global and local news.

Eris Lifesciences Ltd. Concall Transcripts Analysis:


Eris Lifesciences Ltd.'s concall transcripts provide investors with insights into the company's future guidance and outlook. Our website provides access to these critical documents, allowing long-term investors to stay informed on the company's financial health and future growth. Further analysis of this data can be conducted using our premium feature tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Eris Lifesciences Ltd. Investor Presentations Analysis:


Eris Lifesciences Ltd. prepares investor presentations to provide investors with detailed information on the company's operations and performance. These presentations serve as essential resources for long-term investors to study the company's strategic initiatives, offering necessary insights that can impact the stock's value. Our website offers access to these presentations, which investors can download for an in-depth analysis. Our premium feature tools can assist investors in performing an in-depth analysis of the presented data.

Eris Lifesciences Ltd. Promoters and Shareholders Analysis:


Assessing the viability of investing in Eris Lifesciences Ltd.'s stock requires considering the company's promoters and shareholders. Our stock analysis page features essential information about the company's promoters and other shareholders. Long-term investors must consider these elements before making informed investment decisions. Further analysis of the company's shareholding patterns can be conducted using our pre-built screening tools. 

Eris Lifesciences Balance Sheet Overview

Eris Lifesciences has shown significant growth on its balance sheet from March 2020 to March 2024. Particularly noteworthy is the increase in total liabilities from Rs. 1,372.59 Cr. in March 2020 to Rs. 5,106.54 Cr. by March 2024. This growth is largely attributed to a rise in current liabilities which saw an exponential increase, particularly from March 2023.

Eris Lifesciences Reserves Growth

The reserves of Eris Lifesciences have consistently increased, rising from Rs. 1,286.12 Cr. in March 2020 to Rs. 2,510.42 Cr. in March 2024. This indicates a strong retention of earnings which could signify reinvestment into the company and a robust financial health.

Eris Lifesciences Debt Analysis

The company introduced borrowings into its financial structure starting in March 2023 with Rs. 209.47 Cr., escalating to Rs. 485.94 Cr. by March 2024. This shift suggests a new leverage strategy that might be aimed at funding expansion or other significant investments.

Eris Lifesciences Asset Growth

The asset base of Eris Lifesciences has doubled over the four years, with a significant portion of the growth invested in net block and investments. From Rs. 600.64 Cr. in March 2020, the net block grew to Rs. 1,515.56 Cr. by March 2024, complemented by an increase in investments from Rs. 246.03 Cr. to Rs. 1,618.95 Cr.

This analysis is based on the Standalone Balance Sheet of Eris Lifesciences.

Investors looking into Eris Lifesciences might also consider examining more extensive market trends, including sector performance on major indices like NSE and BSE.

Read More
X